随着时间的推移,检查多发病性导致痴呆症的因素
Matthias Klee1, Sheila Markwardt2, Miriam R Elman2
1Department of Social Sciences, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|February 23, 2025
概括
多发病症显著增加痴呆风险,八种慢性疾病占病例的70%以上. 针对心血管健康可能是减少痴呆症发病率的关键.
科学领域:
- 老年学是一门学科.
- 流行病学 流行病学
- 神经学 神经学
背景情况:
- 多种疾病是痴呆症的一个已知的危险因素.
- 以前的研究没有完全捕捉到疾病对痴呆症发病率的综合影响,特别是关于时间和添加效应.
研究的目的:
- 估计特定慢性病对痴呆发病率的共同贡献.
- 为了建模条件的顺序发作中的附加性贡献和时间接近.
主要方法:
- 从健康和退休研究和医疗保险受益人 (1998-2016) 中分析了9944名参与者 (68-99岁).
- 利用验证的索赔算法来编码阿尔茨海默病和相关痴呆症 (ADRD) 和慢性疾病.
- 使用平均归因分数 (LE-AAF) 的纵向延伸来估计条件贡献.
主要成果:
- 八种慢性疾病 (高血压,心肌梗塞,心房动,糖尿病,心力衰竭,缺血性心脏病,中风,关节炎) 占ADRD病例的71.8%.
- 高血压被确定为痴呆风险的最大单一贡献者.
- 对心血管路径到痴呆症内的疾病,信心区间最窄.
结论:
- 多种疾病在痴呆的发病率中起着至关重要的作用.
- 针对心血管疾病的干预措施可能是降低痴呆风险的最有效策略.
- 该LE-AAF方法明确解释了纵向的并发症模式.
相关概念视频
Dementia
88
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
88
Factors Affecting Illness
4.2K
When a person's physical, emotional, intellectual, social development or spiritual functioning is compromised, this deviation from a healthy normal state is called illness. Illness creates stress that in turn harms individuals. Irritation, anger, denial, hopelessness, and fear are behavioral and emotional changes an individual experiences in the phases of illness. A variety of factors influence a person's health and well-being.
For instance, risk factors are connected to illness,...
For instance, risk factors are connected to illness,...
4.2K
Alzheimer's Disease: Overview
425
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
425
Diagnostic and Statistical Manual of Mental Disorders (DSM)
35
The Diagnostic and Statistical Manual of Mental Disorders (DSM) serves as the primary classification system for mental health disorders, providing standardized diagnostic criteria for clinicians and researchers. First published by the American Psychiatric Association (APA) in 1952, the DSM has undergone several revisions to reflect evolving psychiatric understanding. The fifth edition, DSM-5, released in 2013, introduced key updates that expanded diagnostic categories and modified diagnostic...
35
Cognitive Development During Adulthood
45
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
45
Alzheimer's Disease: Treatment
149
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
149


